Rajesh Behl, MD
Hematology & Oncology · Berkeley, CANPI 1104844174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $362,466 of the $583,925 with a category attached, or 62.1%. 60 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 28.3% of the total. 2025 is the largest year on record at $164,984, 3.3 times the $49,418 reported in 2019. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 776 payments — averaging $752.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$165K
- Takeda Pharmaceuticals U.S.A., Inc.$104K
- AbbVie$69K
- Johnson & Johnson$42K
- GSK$29K
- ADC Therapeutics America, Inc.$25K
- plus $150K from 54 others
Across 80 payments — averaging $6862.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$214K
- AbbVie$202K
- Incyte Corporation$72K
- Bristol Myers Squibb$37K
- E.r. Squibb & Sons, L.L.C.$24K
What the payments were for
- Consulting fees$144,68325%
- Speaking & faculty fees$362,46662%
- Travel & lodging$57,88310%
- Food & beverage$18,4523%
- Education$4420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$583,925 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 73 | $1,477,689 |
| JakafiRuxolitinib Phosphate | 77 | $1,438,553 |
| XpovioSelinexor | 43 | $1,282,121 |
| Lenalidomide | 76 | $1,217,848 |
| ImbruvicaIbrutinib | 47 | $723,819 |
| BrukinsaZanubrutinib | 31 | $457,057 |
| VenclextaVenetoclax | 58 | $410,821 |
| CalquenceAcalabrutinib Maleate | 26 | $399,828 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $375,754 |
| IclusigPonatinib Hcl | 12 | $257,383 |
| ScemblixAsciminib Hydrochloride | 17 | $213,075 |
| PromactaEltrombopag Olamine | 15 | $194,496 |
| XareltoRivaroxaban | 79 | $89,619 |
| EliquisApixaban | 70 | $52,675 |
| VarubiRolapitant Hcl | 33 | $42,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $8,255 | $1,477,68973 claims |
| Incyte CorporationJakafi | $19,863 | $1,438,55377 claims |
| Karyopharm Therapeutics Inc.Xpovio | $165,225 | $1,282,12143 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $82 | $723,81947 claims |
| Beigene USA, Inc.Brukinsa | $7,116 | $457,05731 claims |
| AbbVieVenclexta | $69,498 | $410,82158 claims |
| NovartisScemblix, Promacta | $23,971 | $407,57232 claims |
| AstraZenecaCalquence | $11,231 | $399,82826 claims |
| GSKOjjaara | $28,765 | $375,75414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $103,779 | $257,38312 claims |
| Johnson & JohnsonXarelto | $42,385 | $89,61979 claims |
| PfizerEliquis | $5,842 | $52,67570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Berkeley
- Glenn MichelsonBerkeley$521K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.